Search Results
Apr 10, 2026, 07:00 ET Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026
Include:MUC16 in Ovarian CancerMUC16 has high, tumor‑selective expression, with concordance between MUC16 mRNA expression and MUC16 protein abundance by IHC.MUC16 is highly expressed across most histologic subtypes, including the most common subtype,
More news about: Whitehawk Therapeutics, Inc.
Apr 08, 2026, 10:30 ET Primrose Bio Function Generator™ Combinatorial Genetic Technology Case Study Published in PNAS
products with up to 20x higher yields and unparalleled success in supporting a broad range of protein modalities; Prima RNApols®: improved enzymes for mRNA manufacturing; and PeliCRM197®: a commercially validated CRM197 carrier protein used for conjugate vaccines. Several of the world's leading pharmaceutical
More news about: Primrose Bio
Apr 06, 2026, 23:28 ET Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026
platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient,
More news about: Akeso, Inc.
Apr 01, 2026, 08:30 ET Xtalks Announces its Life Science Webinar Calendar for April 2026
DISCOVERY & DEVELOPMENTApr 8 - Translational Imaging to Accelerate Cardiovascular Drug DevelopmentApr 14 - Fast-Tracking IVT mRNA Candidate Selection Through Smarter RNA DesignApr 15 - Accelerating GLP-1 Peptides to Market Through Integrated Formulation &
More news about: Xtalks
Mar 31, 2026, 11:11 ET New FDA Plausible Mechanism Framework Spurs Development of Personalized In Vivo Prime Editing Platform for Urea Cycle Disorders
specifically with the plausible mechanism framework in mind.The team built a two-part prime editing system: a lipid nanoparticle (LNP) that delivers mRNA encoding the editor to the liver, plus a customized adeno-associated virus (AAV) that supplies the short guide RNAs. In liver cell models, the researchers
More news about: Children's Hospital of Philadelphia
Mar 31, 2026, 10:00 ET Samsung Biologics completes acquisition of GSK's manufacturing facility in Rockville, Maryland
cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced
More news about: Samsung Biologics
Mar 31, 2026, 05:40 ET Ivonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026
platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient,
More news about: Akeso, Inc.
Mar 26, 2026, 23:54 ET Akeso Reports Full-Year 2025 Financial Results
AI-powered drug R&D platform, the Dual-Shield ADC technology platform, the Dual-Lock T-cell engager (TCE) technology platform, the Tissue-Smart siRNA/mRNA technology platform, and the cell therapy technology platform. These assets collectively solidifies Akeso's global innovation edge, unlocking 0-to-N
More news about: Akeso, Inc.
Mar 26, 2026, 13:24 ET New TPA Report Finds FDA Costs Soaring, Drug Rejections Rising
walking back a bizarre decision to refuse to examine an application by Moderna for its first mRNA seasonal flu vaccine. Fortunately, FDA Center for Biologics Evaluation and Research Director Vinay Prasad—who played a key role in these decisions—will
More news about: Taxpayers Protection Alliance
Mar 26, 2026, 08:00 ET Samsung Biologics Recognized for Advancing Sustainability at 2026 CDMO Leadership Awards
cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeuticsBy implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced
More news about: Samsung Biologics
Mar 25, 2026, 10:18 ET XtalPi Holdings Announces Full Year 2025 Annual Results
models, extra-hepatic delivery platfoms, and dual-target siRNA platform development, while its breakthrough research mRNA2vec was presented at AAAI 2025, significantly improving mRNA sequence expression and stability.Virtual Cell Platform: In 2025, the Group strategically incubated Boundless
More news about: XtalPi Inc.
Mar 25, 2026, 10:11 ET 晶泰控股發布 2025 年年度業績報告
siRNA 序列發現與化學修飾平台，構建「序列篩選—修飾優化—功能驗證」端到端閉環，自研模型實現精准建模並在多數場景下優於 Advanced ESC 修飾模式。與此同時，集團推進體內藥效預測、肝外遞送及雙靶點 siRNA 平台建設，mRNA2vec 突破性研究成果亮相 2025 AAAI 並顯著提升 mRNA 序列表達與穩定性。虛擬細胞平台：集團於2025年戰略孵化無界進化，專注於利用生物學數據搭建虛擬細胞平台。目前，無界進化已啟動早期融資相關工作，為下一階段研發蓄力。3. 機器人實驗室Physical AI：鍛造「精准雙手」，重塑實驗范式報告期內，我們持續推進自動化機器人實驗室的技術攻堅與流程再造。靈動勺攻克機器人實驗室難題，並已經得到了全球頂級客戶的認可。其核心技術要點如下：
More news about: 晶泰科技
Mar 24, 2026, 22:40 ET Akeso Advances "IO 2.0 + ADC 2.0" Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab
combination approaches aimed at addressing major unmet clinical needs. These include IO 2.0 combinations with other immune checkpoint inhibitors (ICIs), mRNA-based personalized cancer vaccines (such as AK154), DNA-based therapeutics, and additional novel therapeutic platforms. This milestone underscores
More news about: Akeso, Inc.
Mar 24, 2026, 03:31 ET Plasma Fractionation Market to Reach USD 51.06 Billion by 2032, Driven by Rising Demand for Immunoglobulins and Growing Prevalence of Immune Disorders | MarkNtel Advisors
Global mRNA Vaccines and Therapeutics Market: The Global mRNA Vaccines and Therapeutics Market is likely to grow at a CAGR of around 13% during the forecast period, i.e., 2021-26.About
More news about: MarkNtel Advisors
Mar 23, 2026, 08:30 ET Fast-Tracking IVT mRNA Candidate Selection Through Smarter RNA Design, Upcoming Webinar Hosted by Xtalks
and confidence. Dr. Shambhavi Shubham will discuss parallel screening of RNA constructs and LNP formulations, expression and stability across linear mRNA, circular RNA (circRNA) and self-amplifying RNA (saRNA) and how these workflows shorten the path from discovery to clinic.TORONTO,
More news about: Xtalks
Mar 19, 2026, 08:10 ET Ractigen Therapeutics Announces China NMPA IND Approval for Phase II Clinical Trial of saRNA Therapy RAG-01 in Non-Muscle Invasive Bladder Cancer
cellular senescence, to inhibit the abnormal proliferation of bladder cancer cells. This innovative saRNA therapeutic aims to treat NMIBC by increasing p21 mRNA and protein levels.The progression of RAG-01 into Phase II clinical development follows highly encouraging Phase I data from Australia, which
More news about: Ractigen Therapeutics
Mar 18, 2026, 11:06 ET Diakonos Oncology to Showcase DOC1021 (dubodencel) Clinical Data in Pancreatic Cancer and Glioblastoma at AACR and AAN 2026
patient-derived double-loaded dendritic cell therapy that combines tumor lysate and amplified tumor-derived mRNA. The immunotherapy is made with a patient's dendritic cells combined with mRNA and proteins prepared from freshly obtained patient tumor specimens. The unique double-loading approach,
More news about: Diakonos Oncology
Mar 18, 2026, 10:00 ET New England Biolabs® releases EnClose™ Cell-free dbDNA™ Synthesis Kit in collaboration with Touchlight to accelerate DNA and RNA therapeutic development
This kit enables the rapid screening and production of high-purity DNA templates right at the benchtop, cutting months off the development timeline for mRNA vaccines and gene therapies."NEB built upon Touchlight's dbDNA technology by developing the EnClose Cell-free dbDNA Synthesis Kit, which offers
More news about: New England Biolabs, Inc.
Mar 18, 2026, 08:00 ET SK bioscience Secures Funding to Advance RSV Preventive Antibody Development with RIGHT Foundation Support
diversified infectious disease pipeline, including next-generation pneumococcal vaccines, universal coronavirus vaccines, avian influenza vaccines, and mRNA and next-generation vaccine platforms. The company aims to secure global competitiveness through an integrated development strategy connecting R&D,
More news about: SK bioscience
Mar 17, 2026, 22:34 ET Ribo präsentiert auf der RNA Leaders Europe Conference Daten zur extrahepatischen Wirkstoffabgabe
bei der Abgabe an die Niere gute Ergebnisse erzielt. Präklinische Daten zeigen eine spezifische Aufnahme in den proximalen Tubuli, eine Absenkung der mRNA-Spiegel über Spezies hinweg von Nagetieren bis zu nichtmenschlichen Primaten sowie eine Validierung in verschiedenen Krankheitsmodellen.Zusätzlich
More news about: Suzhou Ribo Life Science Co., Ltd.
Mar 17, 2026, 21:26 ET Innorna gibt die Genehmigung des IND-Antrags für IN026 durch die FDA bekannt und treibt damit die Entwicklung von mRNA-basierten Therapien für chronische Stoffwechselerkrankungen voran
IN026 ist eine potenzielle, in ihrer Klasse einzigartige mRNA-Therapie für refraktäre Gicht und markiert den Beginn einer neuen Kategorie von mRNA-Arzneimitteln, die durch die firmeneigene mRNA-LNP-Plattform von Innorna ermöglicht wird.SONDERVERWALTUNGSZONE
More news about: Innorna Co., Ltd.
Mar 17, 2026, 09:30 ET Innorna Announces FDA Clearance of IND for IN026, Advancing mRNA-based Therapies into Chronic Metabolic Diseases
IN026 is a potential first-in-class mRNA therapy for refractory gout, marking the emergence of a new category of mRNA medicines enabled by Innorna's proprietary mRNA–LNP platform.HONG KONG SAR, China and SHENZHEN, China and CAMBRIDGE, Mass.,
More news about: Innorna Co., Ltd.
Mar 17, 2026, 09:30 ET Innorna Announces FDA Clearance of IND for IN026, Advancing mRNA-based Therapies into Chronic Metabolic Diseases
IN026 is a potential first-in-class mRNA therapy for refractory gout, marking the emergence of a new category of mRNA medicines enabled by Innorna's proprietary mRNA–LNP platform.HONG KONG SAR, China and SHENZHEN, China and CAMBRIDGE, Mass.,
More news about: Innorna Co., Ltd.
Mar 16, 2026, 23:00 ET Ribo to present ex-hepatic delivery data at RNA Leaders Europe Conference
platform, good performance in kidney delivery has been achieved, with preclinical data demonstrating proximal tubular specific uptake, and knockdown of mRNA levels cross-species from rodents to NHPs, and validation in various disease models.In addition to kidney, more targeted drug candidates are
More news about: Suzhou Ribo Life Science Co., Ltd.
Mar 16, 2026, 23:00 ET Ribo to present ex-hepatic delivery data at RNA Leaders Europe Conference
platform, good performance in kidney delivery has been achieved, with preclinical data demonstrating proximal tubular specific uptake, and knockdown of mRNA levels cross-species from rodents to NHPs, and validation in various disease models.In addition to kidney, more targeted drug candidates are
More news about: Suzhou Ribo Life Science Co., Ltd.